Kiran K Turaga

List of Publications by Year
in descending order

185 papers	4,610 citations	117625 34 h-index	128289 60 g-index
189 all docs	189 docs citations	189 times ranked	6425 citing authors

#	Article	IF	Citations
1	Are We Harming Cancer Patients by Delaying Their Cancer Surgery During the COVID-19 Pandemic?. Annals of Surgery, 2023, 278, e960-e965.	4.2	65
2	Potential evidence of peritoneal recurrence in Stage-II colon cancer from the control arm of CALGB9581. American Journal of Surgery, 2022, 224, 459-464.	1.8	2
3	Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).. Journal of Clinical Oncology, 2022, 40, 29-29.	1.6	1
4	Survival in total preoperative verus perioperative chemotherapy for patients with metastatic high-grade appendiceal adenocarcinoma undergoing CRS/HIPEC.. Journal of Clinical Oncology, 2022, 40, 90-90.	1.6	0
5	Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 312-312.	1.6	1
6	Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology, 2022, 6, e2100337.	3.0	4
7	The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdominal Radiology, 2022, 47, 1725-1740.	2.1	4
8	The Role of Surgery in Managing Primary and Metastatic Colorectal Cancer. , 2022, , 407-419.		1
9	Utilization of nano-hmC-seal technology to detect epigenetic signatures of peritoneal metastasis in cell-free DNA (cfDNA) in patients with colorectal and high-grade appendiceal cancer.. Journal of Clinical Oncology, 2022, 40, e15510-e15510.	1.6	0
10	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. European Journal of Surgical Oncology, 2021, 47, 4-10.	1.0	16
11	Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. British Journal of Cancer, 2021, 124, 564-566.	6.4	18
12	Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 1777-1785.	1.5	4
13	Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Advanced Colorectal or Ovarian Cancer. Annals of Surgical Oncology, 2021, 28, 7795-7806.	1.5	8
14	ASO Visual Abstract: Differences in Sociodemographic Disparities in Patients Undergoing Surgery for Advanced Colorectal and Ovarian Cancer. Annals of Surgical Oncology, 2021, 28, 430-431.	1.5	1
15	Current Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastrointestinal Malignancies. Advances in Oncology, 2021, 1, 49-61.	0.2	1
16	Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC. Annals of Surgical Oncology, 2021, 28, 6955-6964.	1.5	8
17	Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 9039-9047.	1.5	4
18	ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients. Annals of Surgical Oncology, 2021, 28, 576-576.	1.5	0

#	Article	IF	Citations
19	Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer. Journal of Surgical Research, 2021, 266, 104-112.	1.6	9
20	Surgical team familiarity and waste generation in the operating room. American Journal of Surgery, 2021, 222, 694-699.	1.8	13
21	Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 2021, 28, 4433-4443.	1.5	4
22	A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. Annals of Surgical Oncology, 2021, 28, 4685-4694.	1.5	12
23	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discovery, 2021, 11, 308-325.	9.4	49
24	Multimodal Therapy Including Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Can Result in Long-term Disease-free Survival in Pediatric Desmoplastic Small Round Cell Tumor With Extraperitoneal Disease. Journal of Pediatric Hematology/Oncology, 2021, 43, 228-231.	0.6	1
25	Primary and metastatic peritoneal surface malignancies. Nature Reviews Disease Primers, 2021, 7, 91.	30.5	87
26	Modern Surgical Techniques in Cytoreductive Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 454-459.	1.7	3
27	Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer, 2020, 126, 281-292.	4.1	12
28	Defining and Refining the Role for Surgery and Intraperitoneal Chemotherapy in the Treatment of Peritoneal Surface Malignancies. Annals of Surgical Oncology, 2020, 27, 73-75.	1.5	2
29	Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. Journal of Gastrointestinal Surgery, 2020, 24, 720-727.	1.7	17
30	Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1â€“Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Antiâ€“PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology, 2020, 4, 1180-1186.	3.0	6
31	Discordance of COVIDâ€19 guidelines for patients with cancer: A systematic review. Journal of Surgical Oncology, 2020, 122, 579-593.	1.7	26
32	Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement. Annals of Surgical Oncology, 2020, 27, 5039-5046.	1.5	4
33	Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?. JAMA Network Open, 2020, 3, e2014184.	5.9	6
34	Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States. Annals of Surgical Oncology, 2020, 27, 3097-3102.	1.5	14
35	HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 551-553.	2.5	3
36	Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases. Annals of Surgical Oncology, 2020, 27, 5074-5083.	1.5	15

#	Article	IF	Citations
37	Evaluation of the Association of Perioperative UGT1A1 Genotypeâ€“Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. JAMA Network Open, 2020, 3, e1921290.	5.9	26
38	The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction. Cancer, 2020, 126, 2510-2512.	4.1	3
39	The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer, 2020, 126, 2541-2546.	4.1	21
40	The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer, 2020, 126, 2516-2524.	4.1	7
41	The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations. Cancer, 2020, 126, 2571-2576.	4.1	4
42	The Chicago Consensus on peritoneal surface malignancies: Methodology. Cancer, 2020, 126, 2513-2515.	4.1	9
43	The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors. Cancer, 2020, 126, 2566-2570.	4.1	4
44	The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer, 2020, 126, 2561-2565.	4.1	2
45	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 2020, 126, 2553-2560.	4.1	11
46	The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer, 2020, 126, 2547-2552.	4.1	15
47	The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Cancer, 2020, 126, 2534-2540.	4.1	17
48	The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer, 2020, 126, 2525-2533.	4.1	35
49	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve. Journal of Surgical Oncology, 2020, 122, 85-95.	1.7	9
50	Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).. Journal of Clinical Oncology, 2020, 38, 356-356.	1.6	3
51	Peritoneal Perfusion Techniques. , 2020, , 199-211.		1
52	Implementation of an EMR integrated pathway for the management of malignant bowel obstruction.. Journal of Clinical Oncology, 2020, 38, 813-813.	1.6	0
53	Cytoreductive surgery in selected patients with metastatic gastric cancer treated with systemic chemotherapy.. Journal of Clinical Oncology, 2020, 38, 409-409.	1.6	0
54	5-hydroxymethylation signatures in plasma circulating cell-free DNA as markers for appendiceal and colorectal peritoneal metastasis.. Journal of Clinical Oncology, 2020, 38, 195-195.	1.6	0

#	Article	IF	Citations
55	Implementation of bundled care to reduce surgical site infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 2019, 120, 1044-1045.	1.7	1
56	It Is Time. Annals of Surgical Oncology, 2019, 26, 1963-1966.	1.5	0
57	Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. Journal of Surgical Oncology, 2019, 119, 613-615.	1.7	23
58	Gastric volvulus involving the duodenum. BMJ Case Reports, 2019, 12, e229930.	0.5	0
59	Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 236.	7.1	36
60	Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing â€˜gFOLFIRINOXâ€™ for gastroesophageal adenocarcinoma (GEA).. Journal of Clinical Oncology, 2019, 37, 4050-4050.	1.6	1
61	Registries and Collaborative Groups in Peritoneal Surface Oncology. , 2018, , 507-526.		0
62	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 37-48.	9.4	248
63	Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. Journal of Clinical Oncology, 2018, 36, 2863-2871.	1.6	158
64	Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery, 2018, 164, 1223-1229.	1.9	21
65	Together We Make a Difference. Annals of Surgical Oncology, 2018, 25, 1794-1796.	1.5	0
66	Estimating Surgical Risk for Patients With Severe Comorbidities. JAMA Surgery, 2018, 153, 778.	4.3	6
67	Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis. Surgical Oncology Clinics of North America, 2018, 27, 519-537.	1.5	29
68	Peritoneal Metastases in Colorectal Cancer. Annals of Surgical Oncology, 2018, 25, 2145-2151.	1.5	23
69	Malignant Peritoneal Mesothelioma. , 2018, , 361-368.		0
70	Factors associated with palliative care use in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Research, 2017, 211, 79-86.	1.6	9
71	Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncology, The, 2017, 18, 711-712.	10.7	28
72	Ushering in a New Era for Regional Therapies. Annals of Surgical Oncology, 2017, 24, 868-869.	1.5	0

#	Article	IF	Citations
73	Current management strategies for peritoneal mesothelioma. International Journal of Hyperthermia, 2017, 33, 579-581.	2.5	26
74	Morbidity of curative cancer surgery and suicide risk. Psycho-Oncology, 2017, 26, 1792-1798.	2.3	10
75	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Annals of Palliative Medicine, 2017, 6, 26-35.	1.2	15
76	Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review. Journal of Surgical Oncology, 2016, 113, 628-634.	1.7	24
77	Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. Journal of Oncology Practice, 2016, 12, 928-935.	2.5	50
78	Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Annals of Surgical Oncology, 2016, 23, 912-920.	1.5	28
79	Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis. Cancer Control, 2016, 23, 36-46.	1.8	19
80	Is longâ€term survival possible after marginâ€positive resection of retroperitoneal sarcoma (RPS)?. Journal of Surgical Oncology, 2016, 113, 823-827.	1.7	12
81	Age-based disparities in treatment and outcomes of retroperitoneal rhabdomyosarcoma. International Journal of Clinical Oncology, 2016, 21, 602-608.	2.2	2
82	Regional Therapies for Advanced Cancer: Update for 2016. Annals of Surgical Oncology, 2016, 23, 1452-1453.	1.5	0
83	A literature review of radiological findings to guide the diagnosis of gallbladder adenomyomatosis. Hpb, 2016, 18, 129-135.	0.3	29
84	ReCAP: Cost Differential of Chemotherapy for Solid Tumors. Journal of Oncology Practice, 2016, 12, 251-251.	2.5	12
85	Hepatic Perfusion Therapy. Surgical Clinics of North America, 2016, 96, 357-368.	1.5	1
86	Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 2295-2301.	1.5	4
87	Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Journal of Gastrointestinal Oncology, 2016, 7, 122-8.	1.4	28
88	Conditional probability of survival in gallbladder carcinoma as a prognostic tool for long term survivors.. Journal of Clinical Oncology, 2016, 34, 455-455.	1.6	0
89	Palliative care for hepatocellular carcinoma: Analysis of the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 390-390.	1.6	0
90	Chasing the proverbial unicorn of relative value units (RVU) and block time.. Journal of Clinical Oncology, 2016, 34, 660-660.	1.6	0

#	Article	IF	Citations
91	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers.. Journal of Clinical Oncology, 2016, 34, 339-339.	1.6	0
92	Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials.. Journal of Clinical Oncology, 2016, 34, 641-641.	1.6	0
93	Radiotherapy for intrahepatic cholangiocarcinoma: An analysis of the National Cancer Database.. Journal of Clinical Oncology, 2016, 34, 379-379.	1.6	0
94	Surgical resection versus ablation for hepatocellular carcinoma â‰¤3Âcm: a population-based analysis. Hpb, 2015, 17, 896-901.	0.3	34
95	Retroperitoneal solitary fibrous tumor: surgery as first line therapy. Clinical Sarcoma Research, 2015, 5, 19.	2.3	28
96	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. Hpb, 2015, 17, 1119-1123.	0.3	10
97	Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multiâ€institutional analysis. Journal of Surgical Oncology, 2015, 111, 1035-1040.	1.7	41
98	Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS ONE, 2015, 10, e0139940.	2.5	43
99	Screening Young Adults for Nonhereditary Colorectal Cancer. JAMA Surgery, 2015, 150, 22.	4.3	7
100	Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2015, 111, 213-220.	1.7	146
101	Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. Hpb, 2015, 17, 131-139.	0.3	22
102	Cost and Morbidity Analysis of Chest Port Insertion: Interventional Radiology Suite Versus Operating Room. Journal of the American College of Radiology, 2015, 12, 563-571.	1.8	38
103	Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. Familial Cancer, 2015, 14, 641-649.	1.9	10
104	Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biology and Therapy, 2015, 16, 764-769.	3.4	16
105	Minimally invasive gastrectomy for cancer: current utilization in US academic medical centers. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 3768-3775.	2.4	22
106	Moving Fast and Moving Slow. Annals of Surgical Oncology, 2015, 22, 1631-1633.	1.5	0
107	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 3716-3723.	1.5	83
108	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors. Annals of Surgical Oncology, 2015, 22, 1181-1186.	1.5	23

#	Article	IF	Citations
109	Is local resection adequate for T1 stage ampullary cancer?. Hpb, 2015, 17, 66-71.	0.3	34
110	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of the Fellows. Annals of Surgical Oncology, 2015, 22, 1761-1767.	1.5	40
111	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 1686-1693.	1.5	188
112	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.. Journal of Clinical Oncology, 2015, 33, 353-353.	1.6	0
113	Defining the Role of Adjuvant External Beam Radiotherapy on Resected Adenocarcinoma of the Ampulla of Vater. Journal of Gastrointestinal Surgery, 2014, 18, 2003-2008.	1.7	11
114	Does histology predict outcome for malignant vascular tumors of the liver?. Journal of Surgical Oncology, 2014, 109, 483-486.	1.7	39
115	Surgical management of hepatic hemangiomas: a multi-institutional experience. Hpb, 2014, 16, 924-928.	0.3	66
116	Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?. Hpb, 2014, 16, 70-74.	0.3	26
117	Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1505-1514.	2.4	9
118	Review of the Impact of Antineoplastic Therapies on the Risk for Cholelithiasis and Acute Cholecystitis. Annals of Surgical Oncology, 2014, 21, 240-247.	1.5	18
119	Effect of the experience of surgical chairpersons on departmental National Institutes of Health funding. Journal of Surgical Research, 2014, 192, 293-297.	1.6	3
120	The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Journal of Surgical Oncology, 2014, 110, 779-785.	1.7	134
121	Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World Journal of Surgical Oncology, 2014, 12, 270.	1.9	59
122	Cost Effectiveness of Routine Laparoscopic Ultrasound for Assessment of Resectability of Gallbladder Cancer. Annals of Surgical Oncology, 2014, 21, 2413-2419.	1.5	4
123	Current Trends in the Management of Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2014, 21, 3947-3953.	1.5	38
124	Neutrophilâ€toâ€lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective. Journal of Surgical Oncology, 2014, 109, 95-97.	1.7	36
125	Surgical management of bowel obstruction in patients with peritoneal carcinomatosis. Journal of Surgical Oncology, 2014, 110, 666-669.	1.7	49
126	Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. European Journal of Cancer, 2014, 50, 1747-1757.	2.8	82

#	Article	IF	Citations
127	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2014, 21, 4195-4201.	1.5	141
128	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. Journal of Surgical Oncology, 2014, 110, 302-306.	1.7	8
129	Microwave Ablation for Hepatic Malignancies. Annals of Surgery, 2014, 259, 1195-1200.	4.2	202
130	Immunohistochemistry Ã¢â‚¬â€œ Microarray Analysis of Patients with Peritoneal Metastases of Appendiceal or Colorectal Origin. Frontiers in Surgery, 2014, 1, 50.	1.4	9
131	Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. Journal of Clinical Oncology, 2014, 32, 287-287.	1.6	8
132	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy.. Journal of Clinical Oncology, 2014, 32, 131-131.	1.6	0
133	Cost-effectiveness of routine laparoscopic ultrasound for the assessment of resectability of gallbladder cancer.. Journal of Clinical Oncology, 2014, 32, 272-272.	1.6	0
134	Cost differential among systemic therapies for colon cancer.. Journal of Clinical Oncology, 2014, 32, 583-583.	1.6	0
135	Tumor profiling of 1,306 gastric and esophageal carcinomas and different treatment options.. Journal of Clinical Oncology, 2014, 32, 4017-4017.	1.6	0
136	Cost differential among systemic therapies for breast, bladder, lung, and colon cancer.. Journal of Clinical Oncology, 2014, 32, e17541-e17541.	1.6	0
137	Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 242-249.	0.5	2
138	Surgical Resection in Hepatocellular Carcinoma Patients with Minimal Background Fibrosis: A Strategy in the Era of Organ Shortage. Annals of Surgical Oncology, 2013, 20, 2043-2048.	1.5	12
139	The Frey Procedure for Chronic Pancreatitis Secondary to Pancreas Divisum. JAMA Surgery, 2013, 148, 1057.	4.3	14
140	Right Hemicolectomy for Mucinous Adenocarcinoma of the Appendix: Just Right or Too Much?. Annals of Surgical Oncology, 2013, 20, 1063-1067.	1.5	60
141	Recurrence after microwave ablation of liver malignancies: a single institution experience. Hpb, 2013, 15, 365-371.	0.3	45
142	Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. Hpb, 2013, 15, 794-802.	0.3	3
143	Attributes of a surgical chairperson associated with extramural funding of a department of surgery. Journal of Surgical Research, 2013, 185, 549-554.	1.6	7
144	Novel Multimodality Treatment Sequencing for Extrahepatic (Mid and Distal) Cholangiocarcinoma. Annals of Surgical Oncology, 2013, 20, 1230-1239.	1.5	11

#	Article	IF	Citations
145	Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries. Annals of Surgical Oncology, 2013, 20, 4338-4347.	1.5	8
146	Ablation for Hepatocellular Carcinoma: Validating the 3-cm Breakpoint. Annals of Surgical Oncology, 2013, 20, 3591-3595.	1.5	22
147	Key Factors Influencing Prognosis in Relation to Gallbladder Cancer. Digestive Diseases and Sciences, 2013, 58, 2455-2462.	2.3	24
148	Transplantation versus resection for patients with combined hepatocellular carcinomaâ€“cholangiocarcinoma. Journal of Surgical Oncology, 2013, 107, 608-612.	1.7	80
149	Management of primary hepatopancreatobiliary small cell carcinoma. Journal of Surgical Oncology, 2013, 107, 692-695.	1.7	14
150	The use of isolated limb infusion in limb threatening extremity sarcomas. International Journal of Hyperthermia, 2013, 29, 1-7.	2.5	14
151	Single-institution Outcome Experience Using AlloDermÂ® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects. American Surgeon, 2013, 79, 476-482.	0.8	20
152	Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver.. Journal of Clinical Oncology, 2013, 31, 178-178.	1.6	0
153	Ablation for hepatocellular carcinoma: Validating the 3-cm breakpoint.. Journal of Clinical Oncology, 2013, 31, 277-277.	1.6	0
154	Surgical Treatment of Peritoneal Carcinomatosis from Gastric Cancer. International Journal of Surgical Oncology, 2012, 2012, 1-4.	0.6	5
155	The Surgical Treatment of Breast Cancer in the Elderly: A Single Institution Comparative Review of 5235 Patients with 1028 Patients â‰¥70â€ƒyears. Breast Journal, 2012, 18, 428-435.	1.0	12
156	Measuring the Surgical Academic Output of an Institution: The â€œInstitutionalâ€•H-Index. Journal of Surgical Education, 2012, 69, 499-503.	2.5	34
157	Importance of Histologic Subtype in the Staging of Appendiceal Tumors. Annals of Surgical Oncology, 2012, 19, 1379-1385.	1.5	173
158	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. Journal of Clinical Oncology, 2012, 30, 186-186.	1.6	0
159	Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection?. Journal of Clinical Oncology, 2012, 30, 310-310.	1.6	0
160	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?. Journal of Clinical Oncology, 2012, 30, 256-256.	1.6	0
161	Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. Archives of Surgery, 2011, 146, 870.	2.2	38
162	Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. Ca-A Cancer Journal for Clinicians, 2011, 61, 113-132.	329.8	116

#	Article	IF	Citations
163	An Elevated Body Mass Index Does Not Reduce Survival After Esophagectomy for Cancer. Annals of Surgical Oncology, 2011, 18, 824-831.	1.5	47
164	Determinants of outcomes in pancreatic surgery and use of hospital resources. Journal of Surgical Oncology, 2011, 104, 634-640.	1.7	19
165	Suicide in patients with pancreatic cancer. Cancer, 2011, 117, 642-647.	4.1	57
166	Selective Application of Routine Preoperative Axillary Ultrasonography Reduces Costs for Invasive Breast Cancers. Oncologist, 2011, 16, 942-948.	3.7	16
167	Can We Continue to Ignore Gender Differences in Performance on Simulation Trainers?. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2011, 21, 329-333.	1.0	38
168	Pancreatic Duct Transection: Diagnosis and Management. Journal of Trauma, 2010, 68, E39-E41.	2.3	1
169	Gene Expression Profiling in Breast Cancer. Cancer Control, 2010, 17, 177-182.	1.8	24
170	K-Ras and MSI: Potential Markers of Both Patient Prognosis and Treatment Efficacy. Annals of Surgical Oncology, 2010, 17, 354-355.	1.5	4
171	Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer. Annals of Surgical Oncology, 2010, 17, 1159-1167.	1.5	205
172	Chronic Mesenteric Ischemia:Endovascular Versus Open Revascularization. Journal of Endovascular Therapy, 2010, 17, 540-549.	1.5	54
173	Does laparoscopic surgery decrease the risk of atrial fibrillation after foregut surgery?. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 204-208.	2.4	8
174	Role of Interventional Radiology in the Treatment of Patients with Neuroendocrine Metastases in the Liver. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 765-772.	4.9	32
175	In hospital outcomes after pancreatectomies: An analysis of a national database from 1996 to 2004. Journal of Surgical Oncology, 2008, 98, 156-160.	1.7	21
176	Inguinal Hernias: Should We Repair?. Surgical Clinics of North America, 2008, 88, 127-138.	1.5	25
177	What should doctors wear?. BMJ: British Medical Journal, 2008, 337, a938-a938.	2.3	2
178	A Meta-analysis of Randomized Controlled Trials in Critically Ill Patients to Evaluate the Dose-Response Effect of Erythropoietin. Journal of Intensive Care Medicine, 2007, 22, 270-282.	2.8	7
179	Cholangitis After Coil Embolization of an Iatrogenic Hepatic Artery Pseudoaneurysm. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2006, 16, 36-38.	0.8	18
180	Repair of 104 Failed Anti-Reflux Operations. Annals of Surgery, 2006, 244, 42-51.	4.2	91

#	ARTICLE	IF	CITATIONS
181	Hernia Uterus Inguinale. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2006, 16, 366-367.	0.8	6
182	Assessment of Diaphragmatic Stressors as Risk Factors for Symptomatic Failure of Laparoscopic Nissen Fundoplication. Journal of Gastrointestinal Surgery, 2006, 10, 12-21.	1.7	39
183	Inguinal hernia repair in a developing country. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2006, 10, 294-298.	2.0	9
184	A (9;11)(q34;q13) translocation in a hibernoma. Cancer Genetics and Cytogenetics, 2006, 170, 163-166.	1.0	14
185	A Long-Term Comparison of Plication Configurations for Endoluminal Gastroplication. Journal of Clinical Gastroenterology, 2005, 39, 869-876.	2.2	1